Biodexa Pharmaceuticals Plc (BDRX) Form 6-K — Sep 15, 2026
Biodexa Pharmaceuticals (Nasdaq: BDRX) entered into a warrant inducement agreement on September 14, 2026 under which an accredited holder will exercise all of its Series M, Series N and Series O warrants — 2,204,218 ADSs in aggregate — at a reduced exercise price of $1.05 per share. The closing occurred on or about September 15, 2026, generating approximately $2.3 million in gross proceeds before fees. In consideration for the cash exercise, the holder received new unregistered Series P warrants to purchase up to 4,408,436 ADSs — 200% of the shares exercised — with a $1.05 exercise price, immediately exercisable and a five-year term.
Key figures
- Gross Proceeds
- $2.3 million (approximate, before fees and expenses)
- Offering Price
- $1.05
- Shares Offered
- 2,204,218 ADSs issued upon exercise of Existing Warrants
- Ads ratio
- 1 ADS = 50 ordinary shares
- New warrant ads
- 4408436
- New warrant term
- 5 years, immediately exercisable
- Warrant coverage
- 200% of ADSs issued upon exercise
- Liquidated damages
- $10 per Trading Day per $1,000 of shares (increasing to $20) for registration/legend failures
- Placement agent fee
- 8.0% of gross proceeds
- Series m warrants exercised
- 282952
- Series n warrants exercised
- 701754
- Series o warrants exercised
- 1219512
- Resale registration filing deadline
- within 15 days of the Agreement
- Resale registration effective deadline
- within 45 days of closing
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.